View Complaint
Retainer Agreement
info@rosenlegal.com

Antares shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

Antares Pharma, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Antares Pharma, Inc. (NASDAQ: ATRS) from December 21, 2016 through October 12, 2017, inclusive. The lawsuit seeks recovery of investor losses.

If you purchased shares of Antares during that time and would like to join the action, please click "Join This Class Action," above.

Press Release

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Antares Pharma, Inc. – ATRS

New York, N.Y., November 11, 2017. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Antares Pharma, Inc. (NASDAQ: ATRS) from December 21, 2016 through October 12, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Antares investors under the federal securities laws.

To join the Antares class action, go to http://rosenlegal.com/cases-1237.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Antares had provided insufficient data to the U.S. Food and Drug Administration in connection with its New Drug Application for Xyosted; (2) as a result, Antares had overstated the approval prospects for Xyosted; (3) consequently, Antares’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 22, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1237.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Kevin Chan, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      kchan@rosenlegal.com
      www.rosenlegal.com